10-Q: Codexis Reports Strong Revenue Growth, Net Loss Continues

Codexis, Inc. (CDXS) announced a substantial increase in total revenues for the nine months ended September 30, 2026, driven by strong product and R&D revenue growth, though the company continues to report net losses.

Summary

• Codexis reported a significant increase in total revenues, reaching $19.3 million for the three months ended September 30, 2026, up 124% from $8.6 million in the prior year period. For the nine months ended September 30, 2026, total revenues grew 57% to $49.4 million from $31.5 million in the same period last year.
• Product revenue saw a substantial rise, increasing by 131% to $15.7 million for the quarter and by 79% to $36.1 million for the nine-month period, attributed to higher sales of enzymes for pharmaceutical manufacturing and clinical-stage activities.
• Research and development revenue also increased, up 96% to $3.5 million for the quarter and 18% to $13.3 million for the nine months, driven by milestone and license revenue.
• Despite revenue growth, the company reported a net loss of $8.1 million for the three months ended September 30, 2026, compared to a net loss of $19.6 million in the prior year. For the nine months, the net loss was $28.8 million, a decrease from $53.6 million in the prior year.
• The company secured a new $60 million term loan facility (Trinity Loans) and used $42.5 million of the initial tranche to repay its existing Innovatus loan, which had an effective interest rate of 12.7% as of September 30, 2026.
• Cash and cash equivalents decreased to $29.2 million as of September 30, 2026, from $50.8 million at the end of 2025, while short-term investments increased to $43.4 million from $27.4 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with significant revenue growth offset by continued net losses and substantial debt financing.

Positives

• Total revenues increased significantly by 124% to $19.3 million for the three months ended September 30, 2026, and by 57% to $49.4 million for the nine months ended September 30, 2026.
• Product revenue grew substantially, up 131% to $15.7 million for the quarter and 79% to $36.1 million for the nine months, indicating strong demand for their enzyme products in pharmaceutical manufacturing.
• Research and development revenue also showed robust growth, increasing by 96% to $3.5 million for the quarter and 18% to $13.3 million for the nine months.
• Product gross margin improved to 74% for the three months and 73% for the nine months ended September 30, 2026, up from 64% in the comparable periods of 2025, driven by a shift towards more profitable products.
• Net loss decreased significantly, by 59% to $8.1 million for the three months and by 46% to $28.8 million for the nine months ended September 30, 2026, compared to the prior year periods.
• The company successfully refinanced its debt, securing a new, larger credit facility and repaying the previous, higher-interest loan.

Negatives

• The company continues to incur significant net losses, with a loss of $8.1 million for the three months and $28.8 million for the nine months ended September 30, 2026.
• The accumulated deficit stands at $635.6 million as of September 30, 2026.
• Cash and cash equivalents decreased to $29.2 million from $50.8 million at the end of 2025, indicating a substantial burn rate.
• The company has a history of net losses and may not achieve or maintain profitability.
• The company is dependent on a limited number of customers, with significant revenue derived from a few key clients.
• The company relies on third-party contract manufacturers for large-scale enzyme production, posing supply chain risks.

Risks

• The company has a history of net losses and may not achieve or maintain profitability.
• The novel nature of the ECO Synthesis Manufacturing Platform and its reliance on unproven technologies carries risks of failure to validate performance at scale or gain regulatory acceptance.
• The success of the company's products is dependent on the clinical and market success of its customers' products, which are subject to high regulatory hurdles and inherent uncertainties.
• The company is dependent on a limited number of customers, and the loss or reduction of business from any of these key customers could materially adversely affect its financial performance.
• The company relies on third-party contract manufacturers for large-scale production, creating risks of supply chain disruptions or quality control issues.
• The company may require additional capital in the future, and there is no guarantee that it will be able to raise sufficient funds on favorable terms, if at all.
• The company's intellectual property rights may not be adequately protected, and third parties may claim infringement of their intellectual property.
• The company's business is subject to market and economic conditions, international trade policies, and potential business interruptions from disasters.

Future Outlook

The company believes its existing cash, cash equivalents, and short-term investments, combined with expected revenues and expense management, will provide adequate funds for at least the next 12 months. However, they may require additional capital for business expansion, new product development (including the ECO Synthesis Manufacturing Platform), and potential acquisitions. The company anticipates continued significant operating expenses and net losses in the foreseeable future.

Management Comments

• The company expects to expand its enzymatic tools and process offerings as it further enhances the ECO Synthesis platform to address the overall market needs for scalable and sustainable RNAi manufacturing.
• The company believes its relationships with CDMOs are a vital extension of its strategy to be a technology solutions provider for its customers, offering seamless manufacturing scale-up.
• Management believes that its existing cash, cash equivalents and short-term investments, combined with future expectations for product revenues, research and development revenue, and expense management, will provide adequate funds for planned ongoing operations, capital expenditures and working capital requirements for at least the next 12 months.
• The company may need additional capital if current plans and assumptions change, and may not be able to raise sufficient additional funds on terms that are favorable, if at all.

Industry Context

StockSavvy.ai notes that Codexis operates in the highly competitive biotechnology and pharmaceutical services sector, focusing on enzyme engineering for therapeutic manufacturing. The significant growth in product revenue suggests increasing adoption of their biocatalysis solutions, while the continued investment in R&D and the ECO Synthesis platform highlights the industry trend towards more efficient and sustainable manufacturing processes for complex therapeutics like RNAi.

Comparison to Industry Standards

• The company's product revenue growth of 79% year-over-year for the nine-month period is strong, especially considering the typical long development cycles and regulatory hurdles in the biopharmaceutical industry.
• The improvement in product gross margin to 74% from 64% indicates enhanced operational efficiency or a favorable shift in product mix, which is a positive indicator compared to industry benchmarks where margins can be volatile.
• The continued net loss, while reduced, is not uncommon for companies in the advanced biotechnology and specialized manufacturing solutions space that are heavily investing in R&D and scaling new technologies like the ECO Synthesis platform.
• The company's focus on enzymatic synthesis for RNAi therapeutics positions it against traditional chemical synthesis methods (SPOS) and other emerging enzymatic approaches. Competitors mentioned include Agilent Technologies (chemical synthesis), EnPlusOne Biosciences, and a UK-based consortium.
• The company's debt refinancing, moving from a loan with a 12.7% effective interest rate to a new facility with rates ranging from 10.50% to 11.75%, reflects a strategic move to manage its cost of capital, though the new rates are still substantial.

Legal Proceedings

• The company is not currently a party to any material pending litigation or other material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if future financings involve the issuance of equity securities.
• The company's continued net losses and reliance on future capital raises could impact investor confidence and stock price.
• Customers are increasingly focused on ESG practices, which may influence Codexis' operations and supply chain requirements.
• Creditors and lenders are subject to the terms of the new Trinity Loan and Security Agreement, which includes covenants and security interests in substantially all company assets.

Next Steps

• The company plans to expand its enzymatic tools and process offerings for the ECO Synthesis platform.
• Codexis is working with three large-scale CDMOs to evaluate its ECO platform for GMP-grade siRNA drug substance synthesis.
• The company applied for a building permit during the third quarter of 2026 for its ECO GMP Manufacturing Center.
• The company expects to commence the retrofit of its ECO GMP Manufacturing Center in Hayward, California, during the fourth quarter of 2026.

Key Dates

Recommendation

Codexis demonstrates strong revenue growth and improved gross margins, indicating positive operational momentum. However, the continued significant net losses, substantial accumulated deficit, and reliance on debt financing and potential future capital raises present considerable financial risk. While the refinancing of debt is a positive step, the overall financial health requires careful monitoring. Therefore, a 'hold' recommendation is appropriate, pending sustained profitability and a clearer path to positive cash flow.

Keywords

enzyme technology, biocatalysis, RNAi therapeutics, ECO Synthesis, CodeEvolver, pharmaceutical manufacturing, directed evolution, CDMO